Dr. Pennell on the Cost Effectiveness of NGS in NSCLC
Nathan A. Pennell, MD, PhD
Nathan A. Pennell, MD, PhD, director, Lung Cancer Medical Oncology Program, Cleveland Clinic Taussig Cancer Institute, discusses the cost-effectiveness of next-generation sequencing (NGS) for patients with metastatic non–small cell lung cancer (NSCLC).
A study presented at the 2018 ASCO Annual Meeting reported that using NGS in the screening of patients with metastatic NSCLC can save Center for Medicare and Medicaid Services payers $1.3 million to $2.1 million. The economic impact of NGS compared with sequential single-gene testing modalities to detect genomic alterations in patients with metastatic NSCLC was tested using a decision analytic model. Included in the study were 1 million hypothetical newly diagnosed patients with Medicare and commercial health plans.
Pennell says that although it costs more to pay for a NGS test than a single-gene EGFR test, it is less expensive to pay for a single NGS test than multiple gene panel tests covering EGFR, ALK, ROS1, and BRAF mutations. Ordering 1 NGS test is more cost effective than multiple separate single-gene tests, and it covers all the same genes, and potentially more.